Hexagonal boron nitride (hBN) is a structural analog of graphene, with unique mechanical, thermal, and optical properties that make it desirable for a variety of applications. Production of stable dispersions of well-exfoliated hBN nanosheets, particularly in a nontoxic and inexpensive way, is an important step in the production of hBN macromaterials on an industrial scale. Here, we investigate the use of surfactants for exfoliating and dispersing hBN in aqueous solution. Dispersions in nine different surfactants and water were compared based on dispersion yield, quality, and stability. It was revealed that at low centrifugal force, large-molecular-weight nonionic surfactants disperse the most material. In contrast, when stronger centrifugation is applied, all surfactants produce similar dispersion yields, with dispersions in ionic surfactants containing significantly more exfoliated nanosheets and remaining stable over much longer periods of time. Finally, to demonstrate the scalability and effectiveness of these systems for making macroscopic materials, a dispersion of hBN in sodium dodecyl sulfate (SDS) was used to produce a transparent hBN film that can be deposited on glass and potentially used as an antibacterial or thermally resistant coating.

Boron nitride nanotubes (BNNTs) have attracted attention for their predicted extraordinary properties; yet, challenges in synthesis and processing have stifled progress on macroscopic materials. Recent advances have led to the production of highly pure BNNTs. Here we report that neat BNNTs dissolve in chlorosulfonic acid (CSA) and form birefringent liquid crystal domains at concentrations above 170 ppmw. These tactoidal domains merge into millimeter-sized regions upon light sonication in capillaries. Cryogenic electron microscopy directly shows nematic alignment of BNNTs in solution. BNNT liquid crystals can be processed into aligned films and extruded into neat BNNT fibers. This study of nematic liquid crystals of BNNTs demonstrates their ability to form macroscopic materials to be used in high-performance applications.

The high index of simultaneous incidence of hypertension and hypercholesterolemia in the population of many countries demands the preparation of more efficient drugs. Therefore, there is a significant area of opportunity to provide as many alternatives as possible to treat these illnesses. Taking advantage of the solubility enhancement that can be achieved when an active pharmaceutical ingredient (API) is obtained and stabilized in its amorphous state, in the present work, new drug-drug co-amorphous formulations (Simvastatin SIM- Nifedipine NIF) with enhanced solubility and stability were prepared and characterized. Results show that the co-amorphous system (molar ratio 1:1) is more soluble than the pure commercial APIs studied separately. Aqueous dissolution profiles showed increments of solubility of 3.7 and 1.7 times for SIM and NIF, correspondingly, in the co-amorphous system. The new co-amorphous formulations, monitored in time, (molar fractions 0.3, 0.5 and 0.7 of SIM) remained stable in the amorphous state for more than one year when stored at room temperature and did not show any signs of crystallization when re-heating. Inspection on the remainder of a sample after six hours of dissolution showed no recrystallization, confirming the stability of co-amorphous system. The enhanced solubility of the co-amorphous formulations makes them promising for simultaneously targeting of hypertension and hypercholesterolemia through combination therapy.

Hexagonal boron nitride (h-BN), also known as white graphene, presents an unparalleled combination of properties, including superior mechanical strength, good thermal conductivity, a wide band gap, and chemical and thermal inertness. However, because of its aversion to chemical modification, its applications have not progressed as much as those of carbon nanomaterials. In this manuscript, we show the functionalization of hexagonal boron nitride using alkyl halides in strongly reducing conditions (Billups–Birch conditions). The tunability of the Billups–Birch reaction is demonstrated by alkylating hexagonal boron nitride with 1-bromododecane and varying equivalents of Li to BN. We found that using a 1:20 BN/Li ratio yields the highest chemical modification, as demonstrated using thermogravimetric analysis and Fourier transform infrared spectroscopy, and supported by X-ray photoelectron spectroscopy. Imaging of the functionalized h-BN (fh-BN) revealed that its sheets exfoliate better in isopropanol than pristine h-BN, which displays highly stacked nanostructures. Moreover, bearing alkyl chains confers the nanosheets with improved dispersibility in nonpolar solvents, such as dodecane, and allows the formation of hydrophobic films.

No abstract

Worldwide, 25% of the population suffers from metabolic syndrome (MetS). The treatment of patients with MetS regularly includes drugs prescribed simultaneously to treat several disorders that manifest at the same time, such as hypercholesterolemia, arterial hypertension, and diabetes. To the authors’ best knowledge, there is no previous published analytical method for the simultaneous quantification of drugs used in the treatment of these diseases. In the present study, a rapid high-performance liquid chromatography with a diode-array detector HPLC-DAD methodology was developed for simultaneous quantification of carvedilol (CVD), telmisartan (TEL), bezafibrate (BZT), gliclazide (GZD), and glimepiride (GMP) in bulk and pharmaceutical form. The chromatographic separation of the five pharmaceuticals was achieved on a Hypersil GOLD C18 Selectivity (5 µm, 150 × 4.60 mm2) using a mobile phase of acetonitrile (50%) and 0.02 M KH2PO4, pH 3 (50%) at a flow rate of 1 mL/min and at 25 °C. The total separation time was 9 min. The analytical method was validated following the International Conference on Harmonization guidelines. A reproducible method was obtained with acceptable limits of detection (LOD) and quantification (LOQ) for CVD (0.012 and 0.035 μg mL−1), TEL (0.103 and 0.313 μg mL−1), BZT (0.025 and 0.076 μg mL−1), GZD (0.039 and 0.117 μg mL−1), and GMP (0.064 and 0.127 μg mL−1). The validated method allowed the determination of these drugs in commercial pharmaceutical products both individually and simultaneously. The present method was found to be suitable for simultaneous quantification of the five drugs that are most commonly used in the simultaneous treatment of the metabolic syndrome.